Imunon, Inc. 8-K

What Happened

• Imunon, Inc. (IMNN) filed a Form 8-K (May 4, 2026) reporting that, effective May 1, 2026, the Compensation Committee approved change-in-control (CIC) agreements with three executives: Stacy Lindborg (CEO & President), Douglas Faller (Chief Medical Officer), and Susan Eylward (General Counsel & Corporate Secretary).
• The CIC agreements provide specified severance and benefit protections if the company terminates the executive without cause, or the executive resigns for “good reason,” on or within one year after or within four months prior to a change in control.

Key Details

• Severance payout multiples: CEO Stacy Lindborg would receive a lump-sum equal to 2.5× the sum of (1) her annual base salary and (2) her target annual bonus; the CMO and General Counsel would receive 1.5× that sum.
• Health and life coverage: the company will pay or reimburse premiums for COBRA health continuation and life insurance for up to 24 months for the CEO and up to 18 months for the other two executives.
• Equity treatment: then-outstanding equity awards would be fully accelerated; for option-like awards, exercisability generally continues for the remainder of the original term (with specific timing limits described in the agreements).
• Condition: payment of benefits is subject to the executive signing a release of claims in favor of the Company.

Why It Matters

• These CIC agreements create defined cash and benefit obligations Imunon may owe in the event of a change of control, potentially increasing transaction costs in an acquisition scenario and accelerating equity vesting for key executives.
• For investors, the agreements signal the company’s intent to retain and protect senior leadership around potential corporate transactions; they also outline clear formulas for potential severance exposure that could affect cash needs or dilution if triggered.